Table 2. Prognostic Factors in all enrolled Patient

No-Improvement (n=7) Improvement (n=32) Total patients (n=39) p value
Age (years)b 24.1±7.9 23.2±8.2 23.3±8.1 0.844
Gender, male: femalea 2:5 17:15 19:20 0.407
Hospitalization period (days)b 14.1±3.2 14.0±4.6 14.0±4.4 0.507
Severity
 Objective SCORAD indexb 67.4±13.0 64.8±14.0 65.3±13.8 0.578
  Erythemab 2.4±0.7 2.4±0.5 2.4±0.5 0.761
  Papule/edemab 1.0±0.9 1.6±0.8 1.5±0.8 0.097
  Oozing/crustb 2.1±0.6 1.8±0.9 1.9±0.9 0.419
  Excoriationb 1.9±0.4 2.1±0.9 2.0±0.8 0.419
  Lichenificationb 2.4±0.7 2.0±1.1 2.1±1.0 0.484
  Drynessb 2.7±0.7 2.3±1.1 2.4±1.0 0.113
 Area of skin lesions (%)b 54.1±27.3 49.0±23.8 49.9±24.6 0.654
 Infectious complicationsa 2 (28.6%) 5 (15.6%) 7 (18.0%) 0.603
Laboratory findings
 Serum total IgE (IU/㎖)b 6287.5±5929.0 3541.5±5747.7 (n=30) 4061.0±5881.6 (n=37) 0.092
 Eosinophil count (/㎕)b 1089.0±620.8 1037.0±671.4 1046.3±662.9 0.929
Adherence to treatmenta 2 (28.6%) 25 (78.1%) 27 (84.4%) 0.020*
Concomitant medications
 Antihistaminesa 5 (71.4%) 25 (78.1%) 30 (76.9%) 0.653
 Topical corticosteroidsa 0 (0%) 3 (9.4%) 3 (7.7%) 1.000
Fisher’s exact test
Mann-whitney U-test
p<0.05